drugset
drugset / Trial / NCT05499260

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants

NCT05499260 ↗

Phase 1 Unknown 70 enrolled Shanghai Zhimeng Biopharma, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Epilepsy.

Timeline

Start
2022-05-02
Primary completion
2023-03-02
Completion
2023-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CB03-154 Unknown 5 mg Oral
Subject CB03-154 Unknown 10 mg Oral
Subject CB03-154 Unknown 20 mg Oral
Subject CB03-154 Unknown 40 mg Oral
Subject CB03-154 Unknown 60 mg Oral

Indications

No indication recorded.